Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvin Farrel

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Cancer Discovery|July 31, 2024
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister CellsLiron D Grossmann, Chia-Hui Chen, Yasin Uzun, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
The Open Pediatric Cancer ProjectZhuangzhuang Geng, Eric Wafula, Ryan J Corbett, et al.
Gigascience|September 2, 2025
The Open Pediatric Cancer ProjectZhuangzhuang Geng, Eric Wafula, Ryan J Corbett, et al.
Cell Reports|November 7, 2019
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial DesignJo Lynne Rokita, Komal S Rathi, Maria F Cardenas, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Research Square|August 6, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivityJohn Maris, Isabel Soria-Bretones, Matias Casás-Selves, et al.
Cancer Discovery|July 31, 2024
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister CellsLiron D Grossmann, Chia-Hui Chen, Yasin Uzun, et al.
Nature Communications|June 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivityIsabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
The Open Pediatric Cancer ProjectZhuangzhuang Geng, Eric Wafula, Ryan J Corbett, et al.
Gigascience|September 2, 2025
The Open Pediatric Cancer ProjectZhuangzhuang Geng, Eric Wafula, Ryan J Corbett, et al.
Cell Reports|November 7, 2019
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial DesignJo Lynne Rokita, Komal S Rathi, Maria F Cardenas, et al.
Pageof 4